Eisai Co Ltd (4523):企業の財務・戦略的SWOT分析

【英語タイトル】Eisai Co Ltd (4523) - Financial and Strategic SWOT Analysis Review

GlobalDataが出版した調査資料(DATA904C2724)・商品コード:DATA904C2724
・発行会社(調査会社):GlobalData
・発行日:2018年8月
・ページ数:64
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Eisai Co Ltd (4523) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Eisai Co Ltd (Eisai) is a pharmaceutical company that undertakes the research, development, manufacture and marketing of pharmaceuticals, including over-the-counter (OTC) drugs, prescription medicines and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex (proton pump inhibitor); Aricept, an anti-Alzheimer’s agent; Halaven, a novel anti-cancer agent; Fycompa, an anti-epileptic and peripheral neuropathy treatment, among others. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.

Eisai Co Ltd Key Recent Developments

Jul 27,2018: AAIC 2018 introduces first clinical trial showing intensive blood pressure therapy reduces new cases of mild cognition and dementia
Jul 19,2018: PhoenixBio provides results from studies using PXB-Mouse and PXB-cells being presented at ISSX 2018
Jul 18,2018: Eisai supports relief efforts for flooding in western Japan
Jul 04,2018: Eisai Listed For 17th Consecutive Year In FTSE4GOOD Index Series, An Index For Socially Responsible Investment
Jun 13,2018: Eisai To Establish New Research Facility “Eisai Center For Genetics Guided Dementia Discovery” In Cambridge, Massachusetts In The United States

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Eisai Co Ltd – Key Facts 6
Eisai Co Ltd – Key Employees 7
Eisai Co Ltd – Key Employee Biographies 10
Eisai Co Ltd – Major Products and Services 11
Eisai Co Ltd – History 13
Eisai Co Ltd – Company Statement 21
Eisai Co Ltd – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Joint Venture 25
Section 2 – Company Analysis 26
Company Overview 26
Eisai Co Ltd – Business Description 27
Product Category: Neurology Products 27
Overview 27
Performance 27
Product Category: Oncology Products 27
Overview 27
Performance 27
Product Category: Others 28
Performance 28
Product Category: Americas Pharmaceutical Business 28
Overview 28
Performance 28
Product Category: Asia and Latin America Pharmaceutical Business 28
Overview 28
Performance 28
Product Category: China Pharmaceutical Business 29
Overview 29
Performance 29
Product Category: EMEA Pharmaceutical Business 29
Overview 29
Performance 29
Product Category: Japan Pharmaceutical Business 29
Overview 29
Performance 29
Product Category: Other Business 29
Overview 29
Performance 30
R&D Overview 30
Eisai Co Ltd – Corporate Strategy 31
Eisai Co Ltd – SWOT Analysis 32
SWOT Analysis – Overview 32
Eisai Co Ltd – Strengths 32
Eisai Co Ltd – Weaknesses 33
Eisai Co Ltd – Opportunities 34
Eisai Co Ltd – Threats 35
Eisai Co Ltd – Key Competitors 36
Section 3 – Company Financial Ratios 37
Financial Ratios – Capital Market Ratios 37
Financial Ratios – Annual Ratios 38
Performance Chart 41
Financial Performance 41
Financial Ratios – Interim Ratios 42
Financial Ratios – Ratio Charts 43
Section 4 – Company’s Lifesciences Financial Deals and Alliances 44
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 44
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 45
Eisai Co Ltd, Recent Deals Summary 46
Section 5 – Company’s Recent Developments 47
Jul 27, 2018: AAIC 2018 introduces first clinical trial showing intensive blood pressure therapy reduces new cases of mild cognition and dementia 47
Jul 19, 2018: PhoenixBio provides results from studies using PXB-Mouse and PXB-cells being presented at ISSX 2018 51
Jul 18, 2018: Eisai supports relief efforts for flooding in western Japan 52
Jul 04, 2018: Eisai Listed For 17th Consecutive Year In FTSE4GOOD Index Series, An Index For Socially Responsible Investment 53
Jun 13, 2018: Eisai To Establish New Research Facility “Eisai Center For Genetics Guided Dementia Discovery” In Cambridge, Massachusetts In The United States 54
Jun 13, 2018: Eisai To Establish New Research Facility “Eisai Center For Genetics Guided Dementia Discovery” In Cambridge, Massachusetts In The United States 55
Jun 13, 2018: Industry-Academia-Government Joint Development Agreement Concerning Nucleic Acid Drug Discovery Research Using Novel Nucleic Acid Synthesis And Delivery Technologies Concluded 56
Feb 26, 2018: Launch of Dementia Support Insurance to Provide for Dementia in Japan 57
Feb 20, 2018: EISAI Certified In 2018 As Outstanding Health And Productivity Management Organization (WHITE 500) 58
Feb 20, 2018: EISAI Certified In 2018 As Outstanding Health And Productivity Management Organization (WHITE 500) 59
Section 6 – Appendix 60
Methodology 60
Ratio Definitions 60
About GlobalData 64
Contact Us 64
Disclaimer 64

List of Tables
Eisai Co Ltd, Key Facts 6
Eisai Co Ltd, Key Employees 7
Eisai Co Ltd, Key Employee Biographies 10
Eisai Co Ltd, Major Products and Services 11
Eisai Co Ltd, History 13
Eisai Co Ltd, Subsidiaries 22
Eisai Co Ltd, Joint Venture 25
Eisai Co Ltd, Key Competitors 36
Eisai Co Ltd, Ratios based on current share price 37
Eisai Co Ltd, Annual Ratios 38
Eisai Co Ltd, Annual Ratios (Cont...1) 39
Eisai Co Ltd, Annual Ratios (Cont...2) 40
Eisai Co Ltd, Interim Ratios 42
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 44
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 45
Eisai Co Ltd, Recent Deals Summary 46
Currency Codes 60
Capital Market Ratios 60
Equity Ratios 61
Profitability Ratios 61
Cost Ratios 62
Liquidity Ratios 62
Leverage Ratios 63
Efficiency Ratios 63

List of Figures
Eisai Co Ltd, Performance Chart (2014 - 2018) 41
Eisai Co Ltd, Ratio Charts 43
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 44
Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 45

★調査レポート[Eisai Co Ltd (4523):企業の財務・戦略的SWOT分析] (コード:DATA904C2724)販売に関する免責事項を必ずご確認ください。
★調査レポート[Eisai Co Ltd (4523):企業の財務・戦略的SWOT分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆